
Brief intro:
- Author: Quan Zhou, Hongfei Li, Dario Gerace, Igor Nikolskly, Xi Wang, Jennifer Kenty-Ryu, Jingping Zhang, Matthew Hinderhofer, Elaine Robinson and Douglas A. Melton
- Journal: BioRxiv
- Doi: https://www.doi.org/10.1101/2022.09.15.508091
- Publication Date: 2022 Sep 17
Products/Services used in the paper
Quotation shows PackGene:ssAAV plasmids encoding Firefly luciferase (Luc2) (control) and Luc2-IL2N88D-TGFβ (experimental) (Fig. 6A) were packaged in AAV8-Y447F+Y773F(39) (PackGene) and injected i.p. into 4-week-old female NOD mice (n=10/group) (Jackson Laboratories) at a concentration of 5x10^11 GC/mouse.
Research Field:diabetes
AAV Serotype:AAV8
Animal or cell line strain:4-week-old female NOD mice
Abstract
Transplanting human stem cell-derived islets (SC-islets) is a promising therapy for insulin-dependent diabetes. While functional SC-islets have been produced for clinical application, immune rejection by the host remains a challenge. Present attempts, including chronic immunosuppression and/or physical encapsulation, have some disadvantages. Here we explore a strategy to induce an immune-tolerant environment based on the immune privilege observed in the male gonad. Sperm appears after the maturation of the immune system and development of systemic self-tolerance and the testis protects these autoreactive germ cells by the physical structure of blood-testis-barrier (BTB) and active local immunosuppression. Human SC-islets transplanted into the mouse testis can be physically protected by the BTB and we find that the testis secretes cytokines that induce a population of regulatory T cells (Tregs) that express both CD4 and CD8. We identified cytokines secreted by testis and used a cocktail of IL-2, IL-10, and TGF-β for in vitro co-culture and in vivo transplantation demonstrating improved survival of SC-islets and the induction of Tregs.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
